BrachyDOSE Gets €554K To Prevent Radiation Injuries In Cancer Treatment

BrachyDOSE is a patient-focused tool that uses data to help doctors reduce or even eliminate injuries caused by radiotherapy. It combines a sensor and scanner (hardware) with smart software that uses an injury prediction algorithm to guide treatment decisions.

The solution helps hospitals cut costs, improves the efficiency of radiotherapy, and supports faster recovery for cancer patients.

BrachyDOSE has already partnered with top medical institutions like the National Cancer Centre of Vilnius University Hospital Santaros Clinics and the Oncology Hospital of the Lithuanian University of Health Sciences.

“Our approach is based on the belief that knowledge only creates value when it is applied. That’s why we want to share our competences and knowledge – to make the work of hospitals and doctors easier. Our team includes experts in medical device engineering, data analytics, and medical physics. We are joined by medical oncologists who work directly with patients in hospitals. Soon, we will be recruiting a medical device salesperson,” said co-founder and CEO Neringa Šeperienė.

Šeperienė holds degrees in applied and medical physics, and completed a PhD in materials engineering at Kaunas University of Technology.

Read Also - Symvan Capital Exits Custodiex In Key Digital Asset Custody Deal

The funding round was led by Coinvest Capital, with support from BSV Ventures and angel investor networks LitBAN and EstBAN.

“We are grateful to the venture funds and angel investors who have supported us on our journey. This investment is a major boost that supports the BrachyDOSE team in helping cancer patients avoid the side effects of radiotherapy, while enabling hospitals and doctors to significantly improve the quality of cancer treatment,” said Neringa Šeperienė, founder and CEO of BrachyDOSE.

“Once we obtain CE/MDR certification, we will be able to offer our product to both Lithuanian and international markets.”

“Lithuania is recognised as one of the leading centres for training oncology specialists and scientists. We have modern infrastructure and decades of experience, yet Lithuanian-developed tools and technologies remain limited in this highly dynamic field. BrachyDOSE stands out for its versatility and broad applicability – the technology can be used in any oncology hospital worldwide. This is encouraging news for investors, but more importantly, it may be good news for cancer patients and oncology professionals alike,” said Viktorija Trimbel, Managing Director of Coinvest Capital.

Coinvest Capital led the funding round with a €300,000 investment. Sandra Golbreich Partner at BSV Ventures, highlighted that while radiotherapy plays a crucial role in cancer treatment, doctors have so far depended on estimated dose delivery. This lack of precision often results in side effects for patients underscoring the need for more accurate solutions like BrachyDOSE.

“BrachyDOSE’s data-driven solution introduces a new level of precision that can significantly reduce these side effects. It’s a breakthrough for both patients and clinicians. As early supporters of BrachyDOSE we’ve directly seen Neringa and her team’s unique expertise and strong commitment to improving patient outcomes.

We are proud to continue supporting them and are excited to co-lead this round to help bring such an innovative solution to hospitals worldwide.”

The investment will help BrachyDOSE complete the CE marking and Medical Device Regulation (MDR) certification needed to launch its product in the market.

CE marking confirms that the device meets EU standards for health, safety, and environmental protection, while MDR certification ensures it complies with strict rules for designing, manufacturing and distributing medical devices in the EU.

About BrachyDOSE

Founded in 2024, BrachyDOSE is a next-gen cancer treatment quality control tool that enables precise, error-free radiotherapy using smart hardware and deep learning. It aims to cut treatment costs by up to 5x, save doctors’ time, and speed up patient recovery—impacting over 200 million patients across 2,000+ hospitals globally.